R
Richard J. Beninger
Researcher at Queen's University
Publications - 248
Citations - 10390
Richard J. Beninger is an academic researcher from Queen's University. The author has contributed to research in topics: Amphetamine & Dopamine. The author has an hindex of 54, co-authored 248 publications receiving 10087 citations. Previous affiliations of Richard J. Beninger include University of Western Ontario & McGill University.
Papers
More filters
Journal ArticleDOI
The Role of Dopamine in Locomotor Activity and Learning
TL;DR: It is suggested that the biological substrate of DA-mediated incentive learning is a heterosynaptic facilitation of muscarinic cholinergic synapses, which has important clinical implications since it has been suggested that DA hyperfunctioning underlies the development of schizophrenia.
Journal ArticleDOI
Dopamine D1-like Receptors and Reward-related Incentive Learning
TL;DR: The molecular mechanism underlying DA-mediated incentive learning may involve DA release in association with reward, stimulation of D1-like receptors, activation of the cAMP/PKA cascade and additional intracellular events leading to modification of cortico-striatal glutamatergic synapses activated by stimuli encountered in close temporal contiguity with reward.
Journal ArticleDOI
Pimozide blocks establishment but not expression of amphetamine-produced environment-specific conditioning.
TL;DR: The results of the pimozide experiments may resolve the paradox of neuroleptic drugs, which block dopamine receptors on their first administration but do not have therapeutic effects for a number of days.
Journal ArticleDOI
The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.
TL;DR: This is the first report that the memory impairment produced by anandamide can be attenuated by a cannabinoid antagonist; results suggest that an andamide-induced memory disruption is mediated by CB1 receptors.
Journal ArticleDOI
Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats.
Kelly J. Powell,Noura S. Abul-Husn,Asha Jhamandas,Mary C. Olmstead,Richard J. Beninger,Khem Jhamandas +5 more
TL;DR: In ultra-low doses, naltrexone paradoxically enhances morphine analgesia and inhibits or reverses tolerance through a spinal action and may have implications for chronic treatment with agonist-antagonist combinations.